

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Tocilizumab for treating giant cell arteritis ID1051

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Roche Products (tocilizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • British Cardiac Patients Association • Cardiovascular Care Partnership • Circulation Foundation • Heart UK • Muslim Council of Britain • Pumping Marvellous Foundation • PMRGCA UK (Polymyalgia Rheumatica & Giant Cell Arteritis UK) • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Vasculitis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Society of Cardiovascular Imaging • British Society of Rheumatology • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Health Forum 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • Heart Research Fund • National Institute for Health Research • The Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health Groups</u></p>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Chorley and South Ribble CCG • NHS England • NHS North Manchester CCG • Welsh Government 	<ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.